Hancock Jaffe Laboratories
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert A. Berman
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 70 Doppler Irvine CA United States of America 92618
- IPO Date
- May 31, 2018
- CIK
- 0001661053
- Website
- hancockjaffe.com
- Similar Companies
- Business
- enVVeno Medical Corporation operates as a medical device company, concentrating its efforts on creating advanced tissue-based solutions aimed at enhancing the standard of care for individuals afflicted with venous disease. This Irvine, California-based firm primarily focuses its development pipeline on a leading bioprosthetic implant, the VenoValve, specifically engineered to treat deep venous Chronic Venous Insufficiency (CVI). This condition, where leg vein valves malfunction, leads to impaired blood flow and significant patient discomfort, a challenge for which few effective surgical interventions currently exist. The company's innovative VenoValve, derived from porcine tissue, is designed to be surgically placed into the deep venous system of the leg to restore proper directional blood flow. Having evolved from its former identity as Hancock Jaffe Laboratories, Inc. in October 2021, the company strategically streamlined its focus to address the substantial unmet medical needs within the venous disease market. Further demonstrating its commitment to this area, enVVeno Medical is also advancing a second product candidate, enVVe, aimed at broadening its impact in venous disease treatment. The VenoValve has received FDA Breakthrough Device designation and is currently undergoing its U.S. pivotal SAVVE trial, with previous first-in-human studies showing promising safety and efficacy results in improving patient outcomes.
Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann
Hancock Jaffe To Rebrand As enVVeno Medical
Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021
Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics
Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules
Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve
Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting
HJLI Stock Price Increases Over 35% Pre-Market: Why It Happened
FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve
Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference
First U.S. Patent Issues on Hancock Jaffe VenoValve
Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial
Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial
Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA
Hancock Jaffe Announces Executive Promotions
Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements
Hunt Valve Company Announces Senior Leadership Change
Esports Market - Roadmap for Recovery From COVID-19 | Branding Through Esports to Boost the Market Growth | Technavio
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.69%
The DeanBeat: The Final Hours of Half-Life: Alyx gives us a much-needed peek inside Valve